Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 143.8% in January

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 783,318 shares, an increase of 143.8% from the January 15th total of 321,350 shares. Approximately 5.4% of the shares of the stock are short sold. Based on an average daily volume of 903,297 shares, the short-interest ratio is presently 0.9 days. Based on an average daily volume of 903,297 shares, the short-interest ratio is presently 0.9 days. Approximately 5.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On Hoth Therapeutics

Several large investors have recently made changes to their positions in the stock. DRW Securities LLC bought a new stake in shares of Hoth Therapeutics in the fourth quarter valued at about $257,000. Citadel Advisors LLC bought a new stake in Hoth Therapeutics during the third quarter worth $232,000. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics in the 3rd quarter valued at $184,000. Kestra Private Wealth Services LLC bought a new position in shares of Hoth Therapeutics in the 3rd quarter valued at $51,000. Finally, Geode Capital Management LLC raised its holdings in shares of Hoth Therapeutics by 18.0% during the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after buying an additional 27,577 shares in the last quarter. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Stock Up 4.1%

HOTH stock traded up $0.04 during midday trading on Friday, reaching $1.02. The company’s stock had a trading volume of 711,163 shares, compared to its average volume of 820,270. The business’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.26. Hoth Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.12. The stock has a market cap of $15.82 million, a PE ratio of -0.96 and a beta of 0.56.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). As a group, equities analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOTH has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Thursday, December 4th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.00.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.